We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.

Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM)

AGE: 18 years and older
TYPE: Drug Study (pembrolizumab)
CONDITION: Recurrent Glioblastoma

Study Purpose

The purpose of this study is to test the side effects and efficacy of using Laser Interstitial Thermotherapy (LITT) combined with the Pembrolizumab. LITT is a minimally invasive surgical technique that uses a laser to heat brain tumors. Pembrolizumab is an investigational (experimental) drug that works by helping participants' immune system work correctly to detect and fight cancer cells. Pembrolizumab is experimental because it is not approved by the Food and Drug Administration (FDA), for this use, though it is approved to treat other cancers.

Who Can Participate

Patients 18 years and older with a diagnosis of glioblastoma or gliosarcoma may be eligible for this study.

Learn More About This Research Study

For more information, please call 1-800-641-2422 or contact us using the online form below.

To learn more about this study, please fill out the form below to request more information.
I'm not a robot